ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced ...

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today made ...

Insulet Corporation PODD recently announced the commercial introduction of its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for people with type 1 diabetes (T1D) who are two years of age ...

Insulet has secured an FDA clearance for its latest tubeless insulin pump, the Omnipod 5, a patch-like device capable of adjusting daily doses to changes in the wearer’s blood sugar levels. Designed ...

A year into the rollout of the Omnipod 5 pump, Insulet is still riding high on the automated insulin delivery system’s ever-increasing popularity. Not only did the increase top the highs set in the ...

Pease announced, "For the fourth quarter, we expect total Omnipod revenue growth of 27% to 30% and total company growth of 25% to 28%." She guided for fourth quarter U.S. Omnipod growth of 24% to 27% ...

Insulet, an Acton-based medical device firm specializing in diabetes treatment, has launched commercialization efforts for its tubeless insulin device in the United Kingdom. The tubeless insulin ...

The correction is related to the Omnipod 5 Controller charging port (USB-C port) or cable (USB cable) melting, deforming, or discoloring. Insulet Corporation has voluntarily issued a Medical Device ...